regadenoson

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Function

Conditions

Cardiac Function

Trial Timeline

Dec 1, 2009 → Sep 1, 2010

NCT ID

NCT01026012

About regadenoson

regadenoson is a pre-clinical stage product being developed by Astellas Pharma for Cardiac Function. The current trial status is completed. This product is registered under clinical trial identifier NCT01026012. Target conditions include Cardiac Function.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02697877	Pre-clinical	Completed	Feb 1, 2016	Jul 1, 2018	Coronary Artery Disease
NCT02589977	Approved	Completed	Nov 1, 2015	Jan 21, 2020	Heart Failure, Diastolic
NCT02220634	Pre-clinical	Terminated	Aug 1, 2014	May 25, 2017	Pulmonary Hypertension
NCT01969916	Pre-clinical	Completed	Jun 1, 2014	Jun 1, 2018	Coronary Artery Disease
NCT01779869	Approved	Completed	Jan 1, 2013	Jun 1, 2015	Ischemic Heart Disease
NCT01618669	Phase 3	Completed	Jun 1, 2012	Dec 1, 2014	Coronary Artery Disease (CAD)
NCT01446094	Approved	UNKNOWN	Aug 1, 2011	Jun 1, 2018	Coronary Artery Disease
NCT01334918	Phase 2	Completed	Apr 26, 2011	Jul 2, 2012	Coronary Artery Disease (CAD)
NCT01021618	Pre-clinical	Completed	Jan 1, 2010	Mar 1, 2012	Coronary Artery Disease
NCT01026012	Pre-clinical	Completed	Dec 1, 2009	Sep 1, 2010	Cardiac Function
NCT00881218	Phase 1	Completed	Jun 1, 2009	Dec 1, 2011	Ischemic Heart Disease
NCT00837369	Phase 1	Completed	Apr 7, 2009	Dec 1, 2011	Coronary Artery Disease
NCT00871260	Approved	Completed	Apr 1, 2009	Jun 4, 2014	Coronary Disease
NCT00857792	Pre-clinical	Completed	Mar 1, 2009	Jan 1, 2013	Coronary Disease

Competing Products

20 competing products in Cardiac Function

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	77
Baricitinib (LY3009104) 4 mg	Eli Lilly	Phase 2	52
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	23
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	85
Everolimus (RAD001)	Novartis	Phase 3	77
Deferasirox and Deferoxamine	Novartis	Phase 2	52
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	85
TIN816	Novartis	Phase 2	52
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	85
Pirfenidone + Placebo	Roche	Phase 2	52
Daclizumab	Roche	Phase 1/2	41
Ranolazine + Placebo	Gilead Sciences	Phase 3	76
Insulin infusion with a goal	Novo Nordisk	Phase 3	76
Epinephrine	Pfizer	Approved	84
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	51
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	84
BMS-986224	Bristol Myers Squibb	Phase 1	32
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	51
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	32
Sotagliflozin + Placebo	Sanofi	Phase 2	51

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved